Keyphrases
Ribavirin
100%
Chronic Hepatitis B
79%
Plasma Concentration
60%
Pegylated Interferon
59%
COVID-19
57%
Entecavir
49%
Chronic Hepatitis C
47%
Pharmacogenetics
44%
Hepatitis C Virus
43%
Nave
42%
Telaprevir
39%
Genotype
38%
Sofosbuvir
38%
Genotype E
38%
Peripheral Blood Mononuclear Cells
36%
High Performance Liquid Chromatography-tandem Mass Spectrometry (HPLC-MS/MS)
36%
MS Method
35%
IL28B
34%
Vitamin D Pathway
33%
Virological Response
32%
Retrospective Analysis
31%
Daclatasvir
29%
Hospitalized Patients
29%
Italy
29%
Sustained Virological Response
28%
Mixed Cryoglobulinemia
28%
Pathway Genes
25%
Direct-acting Antivirals
24%
Boceprevir
24%
Rs8099917
23%
Polymorphism
23%
Triple Therapy
22%
HBeAg-negative
22%
Anemia
22%
Gene Polymorphism
22%
GS-331007
21%
Interferon-α (IFN-α)
21%
Peginterferon
21%
Rs12979860
21%
Tenofovir
21%
Interferon-free Therapy
20%
Multivariate Analysis
20%
Hepatitis B e Antigen (HBeAg)
19%
Hepatitis B Surface Antigen (HBsAg)
19%
Hepatitis C Virus Genotypes
18%
SNP
18%
Odds Ratio
17%
Plasma Parameters
17%
Genotype 1
17%
Ritonavir
16%
Pharmacology, Toxicology and Pharmaceutical Science
Ribavirin
91%
Chronic Hepatitis B
78%
Hepatitis B Virus
76%
Infection
55%
Peginterferon
54%
Entecavir
49%
Chronic Hepatitis C
42%
Coronavirinae
41%
Telaprevir
39%
Pharmacogenetics
39%
Interferon
38%
Hepatitis B(e) Antigen
37%
Sofosbuvir
35%
Hepatitis B Antigen
35%
Vitamin D
33%
Diseases
33%
Daclatasvir
30%
Pharmacokinetics
29%
Antivirus Agent
27%
Hepatitis C Virus Genotype 1
27%
Hepatitis C Virus
26%
Boceprevir
24%
Tenofovir
21%
Disease
18%
Hepatitis C
18%
Prospective Study
17%
Hepatitis B
17%
Polyethylene Glycol
17%
Anemia
17%
Proteinase Inhibitor
16%
Cryoglobulinemia
16%
Syndrome
16%
Ritonavir
16%
Ombitasvir
16%
Paritaprevir
16%
Dasabuvir
16%
Liver Cirrhosis
16%
Hospital Mortality
16%
Prevalence
16%
SARS Coronavirus
15%
Peginterferon Alpha
14%
Telbivudine
14%
Fibrosis
13%
Adverse Event
13%
Ultra High Performance Liquid Chromatography
13%
Virus DNA
12%
Tenofovir Disoproxil
12%
Adult Respiratory Distress Syndrome
11%
Simeprevir
11%
Remdesivir
11%
Medicine and Dentistry
Ribavirin
42%
Infection
34%
Hepatitis B Virus
28%
Interferon
25%
COVID-19
23%
Chronic Hepatitis B
18%
Polyethylene Glycol
17%
Hepatitis C Virus
16%
Severe Acute Respiratory Syndrome Coronavirus 2
15%
Sofosbuvir
14%
Hepatitis C Virus Genotype 1
12%
Health Care
12%
Entecavir
11%
Antivirus Agent
11%
Chronic Hepatitis C
11%
Hepatitis C
11%
Prospective Study
11%
Daclatasvir
11%
Peginterferon
10%
Liver Cirrhosis
9%
Odds Ratio
9%
Retreatment
9%
Mixed Infection
9%
Single Nucleotide Polymorphism
8%
Prevalence
8%
Fibrosis
8%
Anemia
7%
Human Immunodeficiency Virus
7%
Simeprevir
7%
Liver Fibrosis
7%
Hepatitis B Antigen
7%
Hepatitis B
7%
Chronic Hepatitis
7%
Velpatasvir
7%
Cohort Effect
7%
Corticosteroid Therapy
7%
Hospital Mortality
6%
Pharmacogenetics
6%
Side Effect
6%
DNA Polymorphism
6%
Hepatitis B(e) Antigen
6%
Erythrocyte
6%
Virus DNA
6%
Observational Study
6%
Logistic Regression Analysis
6%
Adverse Event
5%
Amino Acid
5%
Methylprednisolone
5%
Receptor Gene
5%
Tenofovir
5%